2026-03-19

press FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide The FDA approved a higher 7.2 mg dose of Wegovy (semaglutide), called Wegovy HD, for weight loss and long-term maintenance in adults with obesity or overweight with weight-related conditions, granting the approval under the National Priority Voucher program in 54 days. Clinical data showed the higher dose led to greater weight reduction with a similar safety profile to lower doses, though gastrointestinal side effects and skin sensations were more common. The approval includes a boxed warning about thyroid C-cell tumor risk and is part of the FDA's effort to expedite therapies addressing critical health priorities. Read more →